Women whose menopausal hot flashes cannot be treated with hormone therapy may have an effective non-hormonal alternative, according to a systematic review and meta-analysis published in the European Journal of Medical Research. The analysis pooled results from randomized placebo-controlled trials of neurokinin receptor antagonists, a class of drugs designed specifically to target the neural pathway that drives vasomotor symptoms.
The review was conducted according to PRISMA guidelines and registered with PROSPERO under registration ID CRD420261432009. The researchers searched PubMed, Scopus and Embase, retrieving 183, 329 and 487 records respectively. Eligible studies were randomized placebo-controlled trials evaluating neurokinin receptor antagonists for the treatment of menopausal vasomotor symptoms, and seven trials entered the quantitative analysis.
The primary outcome was the change in the daily frequency of moderate-to-severe vasomotor symptoms from baseline. Secondary outcomes included changes in daily symptom severity scores, treatment-emergent adverse events, drug-related treatment-emergent adverse events, serious treatment-emergent adverse events, and adverse events leading to treatment discontinuation.
On efficacy, the pooled results showed a statistically significant reduction in the daily frequency of moderate-to-severe vasomotor symptoms compared with placebo, with a mean difference of −2.30 episodes per day (95% confidence interval −2.72 to −1.88) and no heterogeneity between trials (I²=0%). Symptom severity also fell significantly, with a mean difference of −0.33 (95% CI −0.41 to −0.25; I²=47%).
The safety picture was more nuanced. Any treatment-emergent adverse event was marginally but significantly more frequent with the active drugs, with a relative risk of 1.06 (95% CI 1.01–1.11). Drug-related treatment-emergent adverse events were also significantly elevated, with a fixed-effect odds ratio of 1.42 (95% CI 1.20–1.67).
Serious treatment-emergent adverse events increased in relative terms, with a relative risk of 1.63 (95% CI 1.08–2.46), although the authors note that absolute event counts remained low across the included trials. Adverse events leading to treatment discontinuation did not reach statistical significance, with a relative risk of 1.46 (95% CI 0.94–2.27).
The certainty of the evidence was appraised using the GRADE framework, and pooled estimates were obtained using random-effects models, except for drug-related treatment-emergent adverse events, which used a fixed-effect odds ratio. The authors caution that combined safety estimates are exploratory because of differences among the included trials in the specific agents used, the doses tested, and the follow-up periods, and that drug-specific trial reports remain the primary basis for assessing tolerability.
The clinical context is important. Menopausal vasomotor symptoms are highly prevalent and can have serious clinical consequences, yet menopausal hormone therapy remains unsuitable for a substantial proportion of women because of absolute or relative contraindications, long-term safety concerns, or patient preference. Neurokinin receptor antagonists have emerged as a mechanistically directed class of non-hormonal pharmacotherapies for this population, but their pooled efficacy and safety profiles across randomized placebo-controlled studies had required systematic quantitative evaluation.
Based on their findings, the authors conclude that neurokinin receptor antagonists confer clinically meaningful and evidence-supported reductions in the frequency and severity of menopausal vasomotor symptoms, and that these agents should be considered effective non-hormonal therapeutic options for women seeking symptom control in whom hormone therapy is contraindicated, undesirable, or clinically inappropriate. They also emphasize that safety signals necessitate individualized clinical interpretation, even though treatment discontinuation was not significantly increased compared with placebo.
As with any meta-analysis, the findings reflect the trials included in the pooled analysis, and the authors note that the review is registered with PROSPERO and follows PRISMA reporting guidelines. The article was published as an open-access review on 27 October 2026.
Subject of Research: Efficacy and safety of neurokinin receptor antagonists for menopausal vasomotor symptoms
Article Title: Efficacy and safety of neurokinin receptor antagonists compared with placebo for menopausal vasomotor symptoms: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials
Article References: Awan, O., Mirza, W., Naeem, M., Irfan, M., Ul Hassan, S. S., Farooq, A., Rashid, S. Y., Ali, R. N., & Al-Emam, A. (2026). Efficacy and safety of neurokinin receptor antagonists compared with placebo for menopausal vasomotor symptoms: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials. European Journal of Medical Research. https://doi.org/10.1186/s40001-026-05375-9
Image Credits: AI Generated
DOI: 10.1186/s40001-026-05375-9
Keywords: menopause, vasomotor symptoms, hot flashes, neurokinin receptor antagonists, systematic review, meta-analysis, hormone therapy alternatives, non-hormonal therapy, drug safety, GRADE, randomized controlled trials, PROSPERO
News Source: Ophelia Keating. (October 28, 2026). Non-hormonal neurokinin antagonists cut hot flashes in pooled trial analysis. Scienmag.
